GAMMA Investing LLC Purchases New Position in Sanofi (NASDAQ:SNY)

GAMMA Investing LLC acquired a new position in shares of Sanofi (NASDAQ:SNY) in the 4th quarter, Holdings Channel reports. The institutional investor acquired 1,624 shares of the company’s stock, valued at approximately $81,000.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Cardinal Capital Management raised its stake in shares of Sanofi by 0.3% in the fourth quarter. Cardinal Capital Management now owns 58,854 shares of the company’s stock worth $2,927,000 after acquiring an additional 201 shares during the last quarter. Daiwa Securities Group Inc. increased its stake in shares of Sanofi by 3.4% in the 4th quarter. Daiwa Securities Group Inc. now owns 6,541 shares of the company’s stock valued at $325,000 after buying an additional 216 shares during the period. Sage Rhino Capital LLC raised its position in shares of Sanofi by 2.8% during the third quarter. Sage Rhino Capital LLC now owns 8,722 shares of the company’s stock worth $468,000 after acquiring an additional 240 shares during the last quarter. Gallacher Capital Management LLC lifted its stake in shares of Sanofi by 4.5% during the third quarter. Gallacher Capital Management LLC now owns 5,715 shares of the company’s stock valued at $307,000 after acquiring an additional 245 shares during the period. Finally, Rise Advisors LLC boosted its holdings in Sanofi by 98.4% in the fourth quarter. Rise Advisors LLC now owns 506 shares of the company’s stock valued at $25,000 after acquiring an additional 251 shares during the last quarter. 10.04% of the stock is owned by institutional investors.

Sanofi Stock Down 0.1 %

Shares of Sanofi stock opened at $49.09 on Tuesday. Sanofi has a 52-week low of $42.63 and a 52-week high of $55.93. The company has a debt-to-equity ratio of 0.19, a quick ratio of 0.87 and a current ratio of 1.27. The business’s 50 day simple moving average is $47.77 and its 200 day simple moving average is $48.28. The firm has a market cap of $124.18 billion, a PE ratio of 24.67, a P/E/G ratio of 1.48 and a beta of 0.61.

Sanofi (NASDAQ:SNY) last announced its quarterly earnings data on Thursday, February 1st. The company reported $0.89 EPS for the quarter, missing analysts’ consensus estimates of $0.94 by ($0.05). The business had revenue of $11.76 billion during the quarter, compared to the consensus estimate of $13.02 billion. Sanofi had a return on equity of 19.69% and a net margin of 10.52%. On average, analysts predict that Sanofi will post 4.09 earnings per share for the current fiscal year.

Sanofi Increases Dividend

The business also recently announced an annual dividend, which will be paid on Thursday, June 6th. Investors of record on Friday, May 10th will be given a $1.478 dividend. The ex-dividend date is Thursday, May 9th. This represents a dividend yield of 2.98%. This is an increase from Sanofi’s previous annual dividend of $1.38. Sanofi’s payout ratio is currently 69.35%.

Wall Street Analysts Forecast Growth

Several brokerages have recently commented on SNY. TheStreet cut shares of Sanofi from a “b” rating to a “c” rating in a research report on Friday, February 9th. StockNews.com cut shares of Sanofi from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, February 27th. Finally, Morgan Stanley started coverage on Sanofi in a research report on Tuesday, January 23rd. They issued an “equal weight” rating and a $55.00 price target on the stock. Three analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $55.00.

Sanofi Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.